Anthony Schwartz Email & Phone Number

Saint Petersburg, Fl, Us

Rockville, Maryland, Us

Primera Therapeutics is focused on addressing the root cause of mitochondrial diseases by developing a first-in-class gene editing platform to target inherited mutant mitochondrial DNA. Primera’s first approach uses a fully customizable TALE-based system to specifically target a stretch of DNA and a molecule that can correct the mutant DNA in the mitochondrial genome.

New York, Ny, Us

BR BioAdvisory works seamlessly with the Brown Rudnick Global Life Sciences Legal team to provide integrated business and legal services to the biotech and pharma sectors. The BR BioAdvisory team leads client business initiatives, supported by Brown Rudnick’s lawyers, and provide additional technical and finance specialists to support client legal needs.

Abvance is a biotechnology company developing a new insulin: glucagon formulation called ABV100 for preventing hypoglycemia. Patients who use ABV100 instead of insulin will experience improved blood glucose control with a safety buffer against hypoglycemia. In addition, ABV100 does not require new behavioral changes or devices and will lighten the daily burden of disease management.

Develops tRNA therapeutics for aging diseases.

Rockville, Maryland, Us

Building patient-focused companies around transformative biotechnologies.

BioVisors is a global life sciences strategic consulting firm. We provide our clients with competitive clinical, scientific and business services based from decades of experience in the biotechnology industry. Our team members have all held former executive positions at various pharmaceutical and medical device companies. We have first hand experience bringing technology from the bench to commercialization.

Baltimore, Md, Us

• Developed and administered educational and research programs for an MBA focused on the startup of biotechnology companies.• Program classwork included venture capital/grant funding, regulatory requirements (FDA & EMA), scientific & clinical trial design, intellectual property and private versus public entities.

New York, Ny, Us

• Advised biotechnology companies on strategy, operations and clinical development of drugs and diagnostics.• Educated internal groups on FDA regulatory processes and biotech investment strategy.

Boston, Us

Nucleate is a free and collaborative student-led organization that facilitates the formation of pioneering life sciences companies.

Boston, Massachusetts, Us

Morphiex is a biotechnology company harnessing the power of the immune system to fight cancer by developing the only dual-functioning #CD47 immune checkpoint inhibitor. Our lead drug candidate, MBT-001, blocks both "don't eat me" and thrombospondin-1 (TSP-1) pathways of #CD47. This enables direct tumor cell killing mediated by T cells, Natural Killer cells, Neutrophils as well as Macrophages.

Worldwide, Oo

Bethesda, Md, Us

• Led a team to develop novel immunotherapy drugs and high throughput screening assays for cancer including small molecules, peptides, antibodies, RNAi and morpholinos• Directed a drug development program with Celgene for cancer to support human trials• Expert in phosphorodiamidate morpholino oligomer (PMO) pre-clinical/clinical development• Published in leading journals, books and international conferences• Considered a Key Opinion Leader in CD47 drug development and clinical trials• Filed US and European patents for immunotherapies for out-licensing• Aided in the formation of a startup biotechnology company based on technology developed at the NIH/NCI

An early stage biotechnology company aimed at commercializing intellectual property developed by its founders for the treatment of cancer, diabetes and Alzheimer’s disease. The company’s lead drug candidate is in a late stage clinical trial for the treatment of sepsis in the veterinary market. • Obtained orphan drug designation for its lead asset in sepsis/endotoxemia• Established IND with US FDA for sepsis/endotoxeima• Designed and managed an ongoing clinical trial for the treatment of sepsis/endotoxemia• Pursued FDA conditional/full regulatory approval through INAD filings• Reviewed Quality Control of cGMP drugs• Applied for and received several grants to run clinical trials• Worked with the CFO to manage accounting and budgetswww.athencion.com

Provides early detection of cancer in presumably healthy individuals by analyzing blood serum.

Chicago, Il, Us

• Led an analytical team to conduct significant due diligence on small to large biotechnology companies which included clinical trial data analysis (Phase I-III), regulatory filings and FDA interactions, FDA advisory committee meetings (ADCOM) and NDA submissions.• Published full initiation reports of drug technology, clinical trials, valuations, financial models and recommendations featured on Bloomberg, The Markets, Wall Street Source, Reuters and Thomson-One.

Interthyr developed diagnostics and therapeutics for endocrine diseases, autoimmune-inflammatory diseases and cancer.• FDA approved diagnostic for Graves’ disease resulting in significant profits • Initiated and conducted a clinical trail for the treatment of endotoxemia/sepsis• Experienced with FDA negotiations for clinical trials in animals and humans• Extensive project management experience• Dealt with various legal situations including licensing agreements and royalty litigation• Responsible for all day to day activities including employee management and finances• Directed laboratory activities across three countries (US, South America, and Italy)• Actively negotiated with venture capitalists and angel investors• Inventor and patent holder on a class of methimazole derivatives for the treatment of autoimmune diseases and cancer• Executed IND-enabling experiments including rat, dog and primate studies• Developed a diagnostic assay for the detection of Wnt5a (a tumor biomarker)• Responsible in obtaining more than 5 million dollars in funding• Developed a drug eluting stent for atherosclerosis• Extensive experience in grant (STTR/SBIR) writing, patent submission, and patent law• Author of several peer-reviewed cancer and autoimmune disease related articles• Presenter and invited speaker at multiple national and international meetings

Specialized in the development of an artificial intelligence based electronic medical records software, high-speed data services and biospecimen storage & processing. • Developed a leading artificial intelligence based electronic health records (EHR) software package• Provided high speed data services and connectivity throughout multiple hospital systems across several states• Designed the first human biorepository for autoimmune & endocrine diseases that stored RNA, DNA, protein and patient blood samples directly linked to patient medical records• Software developed allowed physicians and researchers to mine patient data with clinical samples to support drug development and clinical trial programs• Managed customers, employees, vendors and budgets• The Company’s client base was acquired in 2012

Fort Collins, Co, Us

Evaluated the ability of bone marrow derived mesenchymal stems cells to regenerate bone post-Stereotactic Radiotherapy of osteosarcoma (Dissertation topic). Also initiated an ongoing clinical trial with a novel TLR inhibitor for the treatment of sepsis.

Conducted pre-clinical drug studies focused on targeting the inflammatory TLR signaling pathways and Plasminogen activator inhibitor-1 (PIA-1) in a Type 1 Diabetic rat model.

Athens, Ohio, Us

Developed anti-tumor small molecule inhibitors of TLR in multiple human pancreatic cancer cells lines in vitro and in vivo. Conducted more than 20 pre-clinical tumor implanted animal studies and evaluated growth inhibition of several TLR inhibiting drugs (Thesis Topic).

Atlanta, Ga, Us

Co-Founder of the national youth volunteer involvement task force of the American Cancer Society that is now present in 50 states.

Phd, Biomedical Engineering

Mba, Business Administration

Ms, Biomedical Engineering

Bs, Electrical Engineering & Computer Science